Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Aleshin

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2023
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-upSia V Lindskrog, Karin Birkenkamp-Demtröder, Iver Nordentoft, et al.
European Urology|July 27, 2023
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Zoe June Assaf, Viraj Degaonkar, et al.
Molecular Oncology|December 1, 2023
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumorsEkaterina Kalashnikova, Vasily N Aushev, Allyson Koyen Malashevich, et al.
Nature Medicine|January 16, 2023
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancerDaisuke Kotani, Eiji Oki, Yoshiaki Nakamura, et al.
Cancer Science|November 28, 2021
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsyMasaaki Miyo, Takeshi Kato, Yoshiaki Nakamura, et al.
NPJ Breast Cancer|March 26, 2021
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence riskMark Jesus M Magbanua, Wen Li, Denise M Wolf, et al.
JCO Precision Oncology|December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
Frontiers in Oncology|August 21, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assayThomas Powles, Amanda Young, Halla Nimeiri, et al.
JCO Precision Oncology|March 9, 2022
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsPashtoon M Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.
JAMA Oncology|December 4, 2025
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical TrialGeorge Q Zhang, Jeffrey A Meyerhardt, Qian Shi, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2023
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-upSia V Lindskrog, Karin Birkenkamp-Demtröder, Iver Nordentoft, et al.
European Urology|July 27, 2023
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Zoe June Assaf, Viraj Degaonkar, et al.
Molecular Oncology|December 1, 2023
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumorsEkaterina Kalashnikova, Vasily N Aushev, Allyson Koyen Malashevich, et al.
Nature Medicine|January 16, 2023
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancerDaisuke Kotani, Eiji Oki, Yoshiaki Nakamura, et al.
Cancer Science|November 28, 2021
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsyMasaaki Miyo, Takeshi Kato, Yoshiaki Nakamura, et al.
NPJ Breast Cancer|March 26, 2021
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence riskMark Jesus M Magbanua, Wen Li, Denise M Wolf, et al.
JCO Precision Oncology|December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
Frontiers in Oncology|August 21, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assayThomas Powles, Amanda Young, Halla Nimeiri, et al.
JCO Precision Oncology|March 9, 2022
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsPashtoon M Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.
JAMA Oncology|December 4, 2025
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical TrialGeorge Q Zhang, Jeffrey A Meyerhardt, Qian Shi, et al.
Pageof 7